A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

Hyunsam Kim; Jeongmin Lee; Jeonghoon Ha

doi:10.1002/ccr3.1644

A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

Hyunsam Kim
, Jeongmin Lee
, Jeonghoon Ha

Department of Internal Medicine

The Catholic University of Korea, College of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

Original language	English
Pages (from-to)	1701-1703
Number of pages	3
Journal	Clinical Case Reports
Volume	6
Issue number	9
DOIs	https://doi.org/10.1002/ccr3.1644
State	Published - Sep 2018

Bibliographical note

Publisher Copyright:
© 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Keywords

Graves' disease
agranulocytosis
antithyroid drug

Access to Document

10.1002/ccr3.1644

Cite this

@article{dfcb374de63244dfbe5275ec18a356a8,

title = "A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment",

abstract = "Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.",

keywords = "Graves' disease, agranulocytosis, antithyroid drug",

author = "Hyunsam Kim and Jeongmin Lee and Jeonghoon Ha",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors. Clinical Case Reports published by John Wiley \& Sons Ltd.",

year = "2018",

month = sep,

doi = "10.1002/ccr3.1644",

language = "English",

volume = "6",

pages = "1701--1703",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "John Wiley and Sons Ltd",

number = "9",

}

TY - JOUR

T1 - A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

AU - Kim, Hyunsam

AU - Lee, Jeongmin

AU - Ha, Jeonghoon

PY - 2018/9

Y1 - 2018/9

N2 - Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

AB - Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

KW - Graves' disease

KW - agranulocytosis

KW - antithyroid drug

UR - https://www.scopus.com/pages/publications/85050687825

U2 - 10.1002/ccr3.1644

DO - 10.1002/ccr3.1644

M3 - Article

AN - SCOPUS:85050687825

SN - 2050-0904

VL - 6

SP - 1701

EP - 1703

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 9

ER -

A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this